Warning: The NCBI web site requires JavaScript to function. more...
The evolving role of oestrogen receptor beta in clinical breast cancer.
Speirs V.
Breast Cancer Res. 2008;10(5):111. Epub 2008 Sep 19.
Related citations
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.
Breast Cancer Res. 2008;10(5):R74. Epub 2008 Sep 4.
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V.
Clin Cancer Res. 2008 Aug 15;14(16):5228-35.
The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.
Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR, Ellis IO.
Breast Cancer Res Treat. 2010 Apr;120(3):603-12. Epub 2009 Jun 3.
Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP.
BMC Cancer. 2007 Jul 18;7:131.
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T.
APMIS. 2009 Sep;117(9):644-50.
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.
Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.
Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.
Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'higgins NJ, Hill AD, Young LS.
Br J Cancer. 2004 Nov 1;91(9):1687-93.
Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer.
Davies MP, O'Neill PA, Innes H, Sibson DR, Prime W, Holcombe C, Foster CS.
J Mol Endocrinol. 2004 Dec;33(3):773-82.
Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Yan M, Rayoo M, Takano EA; kConFab Investigators, Fox SB.
Breast Cancer Res Treat. 2011 Apr;126(2):395-405. Epub 2010 May 20.
Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer.
Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirström K.
J Clin Pathol. 2008 Feb;61(2):197-203.
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM.
Breast Cancer Res. 2008;10(5):R89. Epub 2008 Oct 23.
Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
Acta Oncol. 2009;48(4):514-21.
Metastases of prostate cancer express estrogen receptor-beta.
Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E.
Urology. 2004 Oct;64(4):814-20.
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K.
Breast Cancer Res. 2008;10(5):R79. Epub 2008 Sep 22.
Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer.
Lai LC, Erbas H, Lennard TW, Peaston RT.
Int J Cancer. 1996 Jun 11;66(6):743-6.
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
Breast Cancer Res. 2008;10(5):R88. Epub 2008 Oct 17.
Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer.
Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara H, Noguchi S.
Ann Oncol. 2008 Jan;19(1):68-72. Epub 2007 Oct 22.
Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
Papaldo P, Di Cosimo S, Ferretti G, Carlini P, Fabi A, Cecere F, Cognetti F.
Breast. 2006 Apr;15(2):269-72. Epub 2005 Aug 29.
A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis.
Neven P, Van Gorp T, Deraedt K.
Breast Cancer Res. 2008;10(5):109. Epub 2008 Sep 4.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on